Nathan Fowler, MD
Associate Professor of Medicine, Department of Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston, TX, USA
Since joining MD Anderson, Prof. Fowler have assumed lead of the indolent lymphoma research team and built a robust clinical research program focusing on developing novel biologic regimens with next generation targeted agents. Their team is leading several investigator initiated studies with lenalidomide, ibrutinib, idelalisib, and novel anti-CD20 antibodies among others. They are currently conducting frontline studies with lenalidomide plus obinutuzumab and lenalidomide, rituximab, and ibrutinib as well as over 12 trials with novel agents in relapsed disease. In the majority of these studies, they have secured industry funding to preform unique correlative work to discover biomarkers of response and further elucidate agents’ effect of the immune microenvironment. In collaboration with Sattva Neelapu and Eric Davis, they have translated their early findings into a novel immunoassay which may predict response to immunotherapy. This assay is part of a flagship project in the MDACC moonshot program, and will be validated in ongoing studies.
The goal of Prof. Fowler ongoing research is to further develop novel, targeted therapeutic regimens utilizing biologic agents to treat non-Hodgkins lymphoma. He serves as Co-Director of Clinical and Translational Research in the Department of Lymphoma/Myeloma and leads the New Drug Development and Indolent Lymphoma Research Groups. He serves as chairman of several phase I, investigator-initiated phase II, and pivotal international phase III studies for patients with non-Hodgkins lymphoma. He has also had the opportunity to develop collaborative relationships with basic scientists across the institution to further understand the biologic mechanisms that drive B-cell malignancies and integrate cutting edge translational assays into ongoing clinical studies.Worldwide research on the immune microenvironment in indolent lymphoma is fragmented, and often conflicting. In 2013, Prof Fowler established the first annual Summit on the Immune Microenvironment. This annual international meeting, now in its third year, brings together key investigators from the US and Europe to collaborate and identify key areas of study in immunotherapy for lymphoma.